A blood pathogen reduction system that treats donated blood components to inactivate viruses, bacteria and other harmful microbes before transfusion. Investors care because it addresses safety risks in the blood supply—similar to a disinfectant for donated blood—reducing the chance of transfusion-transmitted infections, lowering regulatory and liability risk, and creating demand from hospitals and blood banks when safety standards or outbreaks increase.
plateletsmedical
Platelets are tiny cell fragments in the blood that act like emergency patch kits, clumping together to stop bleeding and help wounds heal. Their count and function are key indicators of bleeding risk, infection, or disease, so changes can drive demand for drugs, diagnostic tests, blood products, or medical devices; for investors, that means clinical trial results, regulatory approvals, supply constraints, or new technologies affecting company value.
plasmamedical
Plasma is the pale yellow liquid portion of blood that carries proteins, antibodies and other components which can be separated and processed into therapies, diagnostic products and vaccines. For investors, plasma functions like a raw material: its supply, collection costs, quality controls and regulatory oversight directly affect revenue, margins and growth prospects for companies that collect plasma or make plasma-derived products.
pathogen inactivationmedical
Pathogen inactivation is a set of processes used to kill or neutralize viruses, bacteria and other infectious agents in biological materials such as blood products, plasma or cell therapies. Think of it like pasteurizing milk or disinfecting a surface: it reduces the risk that a product will transmit infection to a patient. For investors, this matters because effective pathogen inactivation can lower safety-related recalls and regulatory hurdles, support broader market access, and influence production costs and product pricing.
transfusionsmedical
Transfusions are medical procedures that restore a patient’s blood or key components—such as red cells, plasma, or platelets—by transferring donated products into a vein, like refilling a car’s fuel tank to keep it running. They matter to investors because safety concerns, supply shortages, regulatory approvals, manufacturing capacity and evolving clinical guidelines directly affect demand and revenue for hospitals and companies that collect, process or sell blood products.
chikungunyamedical
A mosquito‑transmitted viral infection that causes sudden fever, severe joint pain, fatigue and sometimes rash; symptoms can linger for weeks to months and occasionally lead to more serious complications. It matters to investors because outbreaks can disrupt local workforces, strain healthcare systems and spur demand for diagnostics, treatments, vaccines and travel or insurance adjustments—similar to how a bad seasonal flu can ripple through businesses and public services.
denguemedical
Dengue is a mosquito‑transmitted viral illness that can cause high fever, severe headache, joint pain and, in some cases, life‑threatening complications. Investors care because outbreaks can disrupt workforces, strain healthcare systems, change travel and tourism patterns, and drive demand for diagnostics, treatments and vaccines—similar to how a severe seasonal illness can affect multiple parts of the economy and company performance.
zikamedical
Zika is a mosquito-spread virus that can cause fever, rash and, in some cases, serious birth defects when pregnant people are infected; it spreads quietly and can touch communities beyond obvious hotspots. For investors, Zika is important because outbreaks can change demand for medical tests, vaccines, mosquito-control products and travel services, and can prompt regulatory action and government spending—similar to how a sudden storm shifts priorities and spending across many industries.
See more from StockTitan in Google Search and AI answers.Adds StockTitan as a preferred source · opens Google
CONCORD, Calif.--(BUSINESS WIRE)--
Cerus Corporation (Nasdaq: CERS) announced today the signing of a new, four-year supply agreement with Établissement Français du Sang (EFS), the French Blood Establishment, for the INTERCEPT Blood System. The agreement covers the INTERCEPT Blood System for platelets and plasma as well as the next generation, LED-based INT200 illumination device.
“We are proud to announce a new four-year supply agreement with the French Blood Establishment,” said Christian Boutemy, Cerus’ vice president of international commercial operations. “EFS has been a global leader in the adoption of pathogen inactivation technologies to help safeguard the blood supply and enhance patient safety. This agreement further underscores our shared, enduring commitment to ensuring safe transfusions for patients.”
The EFS distributes approximately 330,000 units of platelets annually across 13 regional centers in continental France and overseas territories. The INTERCEPT Blood System for platelets has been used in France since 2006, with broader nationwide adoption following a nationwide rollout in 2017. INTERCEPT is also used throughout French overseas territories, including La Réunion, Guadeloupe, and Martinique. Implementation in those island territories was driven by the need to maintain a safe platelet supply during outbreaks of chikungunya, dengue and Zika in these tropical regions.
ABOUT CERUS
Cerus Corporation is dedicated solely to safeguarding the world’s blood supply and aims to become the preeminent global blood products company. Headquartered in Concord, California, the company develops and supplies vital technologies and pathogen-protected blood components to blood centers, hospitals, and ultimately patients who rely on safe blood. The INTERCEPT Blood System for platelets and plasma is available globally and remains the only pathogen reduction system with both CE mark and FDA approval for these two blood components. In the U.S., the INTERCEPT Blood System for Cryoprecipitation is approved for the production of Pathogen Reduced Cryoprecipitated Fibrinogen Complex (commonly referred to as INTERCEPT Fibrinogen Complex), a therapeutic product for the treatment and control of bleeding, including massive hemorrhage, associated with fibrinogen deficiency. The INTERCEPT red blood cell system is under regulatory review in Europe, and in late-stage clinical development in the U.S. For more information about Cerus, visit www.cerus.com and follow us on LinkedIn.
Cerus, INTERCEPT, and the Cerus logo are trademarks of Cerus Corporation.
Forward-Looking Statements
Except for the historical statements contained herein, this press release contains forward-looking statements concerning Cerus’ products, prospects and expected results, including statements relating to: the expected benefits and performance of the INT200 illumination device; the potential for the INT200 to support geographic expansion and future growth of the INTERCEPT business; Cerus’ expectations regarding the transition of existing customers to the INT200 and the adoption of INTERCEPT in additional geographies; the expected duration, scope and impact of the supply agreement with Établissement Français du Sang; and other statements that are not historical fact. Actual results could differ materially from these forward-looking statements as a result of certain factors, including, without limitation: risks associated with the commercialization and market acceptance of, and customer demand for, the INTERCEPT Blood System, including the risks that Cerus may not (a) effectively commercialize the INT200, (b) realize meaningful revenue contribution from the INT200 in the near term or at all and/or (c) effectively expand its commercialization activities into additional geographies; risks associated with Cerus’ dependence on significant customers, including national blood services such as EFS, and the variability of customer purchasing patterns; risks related to the highly concentrated market for the INTERCEPT Blood System; risks associated with Cerus’ ability to maintain and grow customer relationships and renew or extend customer agreements; risks associated with macroeconomic developments, including ongoing military conflicts, new or increased tariffs, escalating trade tensions, inflation, rising interest rates and foreign exchange volatility and the resulting global economic and financial disruptions; risks related to Cerus’ ability to maintain an effective, secure manufacturing supply chain, including the risks that (a) Cerus’ supply chain could be negatively impacted as a result of macroeconomic developments, (b) Cerus’ manufacturers could be unable to comply with extensive regulatory agency requirements, and (c) Cerus may be unable to maintain its supply agreements with its third-party suppliers; risks related to regulatory review and approval processes, including the risk that Cerus may be unable to obtain and maintain requisite in-country regulatory approvals necessary to commercialize the INT200 in a timely manner or at all; risks related to product safety; risks related to Cerus’ ability to demonstrate to the transfusion medicine community and other healthcare constituencies that pathogen reduction and the INTERCEPT Blood System are safe, effective and economical; risks associated with Cerus’ need for additional funding; risks associated with the impact of legislative or regulatory healthcare reforms that may make it more difficult and costly for Cerus to produce, market and distribute its products; as well as other risks detailed in Cerus’ filings with the Securities and Exchange Commission, including under the heading “Risk Factors” in Cerus’ Annual Report on Form 10-K for the year ended December 31, 2025, filed with the SEC on March 2, 2026. Cerus disclaims any obligation or undertaking to update or revise any forward-looking statements contained in this press release.
